optimal mapk inhibition as a key component of therapeutic strategies for kras mutant cancers
Published 5 years ago • 208 plays • Length 33:37Download video MP4
Download video MP3
Similar videos
-
33:37
optimal mapk inhibition as a key component of therapeutic strategies for kras mutant cancers
-
47:45
resistance in braf and kras mutant cancers - by ryan corcoran, md, phd
-
47:43
emerging therapies to optimize map kinase blockade and intercept compensatory signaling
-
21:36
strategies for overcoming kras mutations
-
1:37
treatment strategies for kras-mutant nsclc with co-mutations
-
26:09
how to improve on the outcome in ras mutant tumors
-
30:55
targeting the phosphoinositide-3 kinase (pi3k) pathway in breast cancer - josé baselga, md
-
5:29
development of kras g12c-targeted therapy in nsclc
-
21:11
resistance to mapk pathway inhibition in braf mutant colorectal cancers
-
7:34
ras-mapk pathway | ras-mapk in cancer | the map kinase (mapk) signalling pathway
-
32:30
braf: the first prevalent oncogene target to show single-agent responsiveness
-
5:23
potential synergy of mek /pd-l1 inhibitors in kras-mutant mcrc
-
46:29
oncogene additivity in the pi3k pathway in cancer
-
7:00
kras-mutant nsclc
-
45:21
ras oncoproteins therapeutic vulnerabilities
-
21:11
resistance in colorectal cancer by ryan b. corcoran, md, phd
-
6:10
inhibition of mek to treat cancer: focus on melanoma
-
59:47
clinical proteogenomic tumor analysis consortium
-
1:00:48
antonio baines - oncoproteins k ras and pim kinases as molecular targets in pancreatic cancer